View Post

Monoclonal Antibody Combo Effective Against Delta Variant

In COVID-19, Latest News by Precision Vaccinations

The Assistant Secretary for Preparedness and Response (ASPR) and the US Food and Drug Administration (FDA) announced on August 27, 2021, changes in the authorized use of monoclonal antibodies bamlanivimab and etesevimab administered together under Emergency Use Authorization (EUA) 094.
The ASPR will resume distribution of bamlanivimab and etesevimab together and etesevimab alone to pair with the existing supply of bamlanivimab at a facility for use under EUA.